Oxis Intl : Vol 25 000 000 Titres Attendu

Renseignements sur la Discussion

- 09/12/2010 10:40

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Semaine crutiale pour la biotech

Réponses

Suivant > >

Afficher tous les Messages

Retourner à la liste

Rafraîchir

31 Réponses
1 2

1 de 31 - 09/12/2010 11:41

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Oxis Intl : Toujours beaucoup de volumes à l'approche de la mi-novembre
Mercredi 10 novembre 2010 à 17:02 Imprimer

(c) dr
(Tradingsat.com) - L'effervescence se poursuit sur Oxis International, dont les actions restent activement négociées à la Bourse de Paris à quelques jours du lancement programmé du premier produit de la société biopharmaceutique américaine.

Le titre est stable (0,11 euro) mais les volumes dépassent les 29 millions de titres échangés à 17h30, après le record de 41,7 millions de la veille.

L'annonce d'un accord financier conclu avec Gemini Pharmaceuticals a mis le feu aux poudres hier.

Ce partenaire financier, qui a décidé d'investir 250 000 dollars dans le capital d'Oxis International et de lui octroyer une ligne de crédit de 750 000 dollars, est avant tout le principal partenaire industriel du groupe dirigé par Antony Cataldo.

Le dirigeant n'a d'ailleurs pas manqué de souligner hier que Gemini avait acheté des actions à un prix nettement supérieur au cours de Bourse (d'avant l'annonce de l'accord), le signe selon lui de la confiance de Gemini dans le potentiel des projets du groupe.

Pour Oxis International, qui s'est positionné pour devenir un « nouvel entrant dans l'industrie nutraceutique et cosméceutique » (à la croisée entre la cosmétique, la pharmaceutique et le médicament), le moment clé se rapproche. Le lancement de son premier produit, le lancement de l'ErgoFlex, un anti-oxydant formulé pour lutter contre les douleurs articulaires, a été annoncé pour "mi-novembre".

La formule du produit repose sur le composé breveté antioxydant L-Ergothioneine. Il y a quelques jours, Oxis a rappelé l'importance de sa propriété intellectuelle sur ce composé, protégé par 12 brevets.

Oxis a d'ailleurs récemment annoncé le règlement d'un litige avec le groupe de cosmétiques Estee Lauder, sur deux de ces brevets, dont Oxis a obtenu la pleine propriété.

Copyright (c) 2006-2010 Tradingsat.com. Tous droits réservés.

2 de 31 - 09/12/2010 11:53

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Oxis Intl : Vise "une forte croissance", veut créer de la valeur pour l'actionnaire
Mercredi 3 novembre 2010 à 16:09 Imprimer

(Tradingsat.com) - En marge de l'annonce du lancement de son premier produit, l'ErgoFlex, prévu pour mi-novembre, la société américaine Oxis International (cotée à New York et Paris) a rappelé hier le chemin parcouru par sa nouvelle équipe de management « dans le but de créer un valeur actionnariale durable ».

Les dirigeants affichent ainsi leur satisfaction d'avoir « créé les fondations permettant d'entrer dans une phase commerciale et de se préparer à une forte croissance ».

Après la prochaine mise sur le marché, dans quelques jours de l'« ErgoFlex », « une formule efficace pour les douleurs articulaires », le groupe prévoit de nouveaux lancements « plus tard cette année et jusqu'au début de 2011 ». Oxis évoque des formulations anti-âge, ou destinées à améliorer la santé cardiovasculaire, ou encore la vue.

Pour son entrée sur le marché nutraceutique, Oxis a choisi d'utiliser les mails directs « afin d'accroître la sensibilisation et l'acceptation de ses produits ». Il compte aussi sur les ventes Internet ainsi que sur les publicités TV et radio, des supports « très efficaces pour les produits de nutrition et de soin personnels ».

« Par rapport aux points de vente traditionnels, ces canaux de vente directe aux consommateurs offrent des marges sensiblement plus élevées et [permettent] une entrée sur le marché potentiellement plus rapide », souligne Oxis.

Pour la suite, le groupe réfléchit déjà à d'autres produits, toujours basés sur son composé breveté l'Ergothioneine, tels que des barres nutritives, des boissons énergétiques, ainsi qu'une ligne de produits de soins personnels (des crèmes anti-âge, cosmétiques, et des traitements pour les cheveux et du cuir chevelu...).

Copyright (c) 2006-2010 Tradingsat.com. Tous droits réservés.

3 de 31 - 11/12/2010 08:58

xcountry Messages postés: 22 - Membre depuis: 29/3/2010

Bonjour,

Comment vas tu ? Le potentiel de cette société, ainsi que du titre mes semble très intéressant. Penses tu que nous allons avoir des news d'ici peu concernant l'ergoplex et d'un partenariat éventuel ? Ce titre pourrait surement sortir du statut de penny stock rapidement avec ce nominal.

Bon week end.

4 de 31 - 04/1/2011 13:55

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Des licences aux etats unis sont en cours de négociation.

Un retour des volumes est constaté depuis quelques jours, de plus la diversité des actifs de la société vont vers une croissance accompagné aussi par une tendance de marché du médicaments

5 de 31 - 04/1/2011 19:24

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Oxis ne cible pas uniquement les pharmacies, mais aussi des points de vente de la grande distribution .

OXIS International, Inc., (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO).

"This patent application filing is an important step toward expanding our already strong intellectual property portfolio for Ergothioneine," said Bernie Landes, president of OXIS International. "The application also supports the recent launch of ErgoFlex™ for joint pain relief. ErgoFlex is the first in a series of ERGO-based commercial products we plan to introduce in coming months."

Specifically, the application relates to the use of Ergothioneine compositions containing one or more additional nutraceutical compounds to improve a variety of health related factors, including, but not limited to, brain health, joint health, eye health, mitochondrial optimization/improvement and to reduce inflammation and pain.

The application also includes information and data from several clinical and animal studies examining Ergothioneine's safety profile and benefits relating to health issues associated with oxidative stress.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets. For more information, please visit www.oxis.com

6 de 31 - 04/1/2011 20:41

xcountry Messages postés: 22 - Membre depuis: 29/3/2010

Cette boite a surement un gros potentiel. Maintenant est de savoir dans quelle proportion Gemini va s'investir dans oxis. Surtout que Gemini est leader aux US.

Rappel.:
[Gemini Pharmaceuticals a investi 250.000 Dollars dans son capital, et lui a octroyé 750.000 Dollars de ligne de crédit. La part en capital est représentée par l'acquisition de 1.666.667 actions de préférence convertibles à 0,15$ par titre (soit une prime de 50% sur le cours actuel des actions de la société). Pour le management d'Oxis, l'investissement de Gemini est le signe du potentiel de ses produits.]

7 de 31 - 07/1/2011 09:01

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

OXIS International Files Patent Application for Methods and Compositions Using Ergothioneine
.
Companies:OXIS INTL INC.Related Quotes
Symbol Price Change
OXIS.OB 0.14 0.00

{"s" : "oxis.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: OXIS International, Inc. On Monday December 20, 2010, 7:00 am EST
BEVERLY HILLS, Calif., Dec. 20, 2010 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board:OXIS.ob - News) today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO).

"This patent application filing is an important step toward expanding our already strong intellectual property portfolio for Ergothioneine," said Bernie Landes, president of OXIS International. "The application also supports the recent launch of ErgoFlex™ for joint pain relief. ErgoFlex is the first in a series of ERGO-based commercial products we plan to introduce in coming months."

Specifically, the application relates to the use of Ergothioneine compositions containing one or more additional nutraceutical compounds to improve a variety of health related factors, including, but not limited to, brain health, joint health, eye health, mitochondrial optimization/improvement and to reduce inflammation and pain.

The application also includes information and data from several clinical and animal studies examining Ergothioneine's safety profile and benefits relating to health issues associated with oxidative stress.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets. For more information, please visit www.oxis.com

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may," "potential" or the negative of those words or other similar expressions words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks and uncertainties inherent in our business, including, without limitation the risks of obtaining possibly required regulatory approvals, the timing of product introductions, the level of market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

8 de 31 - 09/1/2011 16:54

xcountry Messages postés: 22 - Membre depuis: 29/3/2010

Bonjour djurjura,

Comment vas tu ?

Je t'ai trouvé du nouveau sur oxis, ils vont recapitaliser la société via des obligations et autres dérivés convertibles en actions ordinaire(voir le lien ci-dessous). Ils font une pierre Deux coup. Theoreme se renforce dans le capital, il vont remettre dans le capital 2,5 millions de dollar pour obtenir les 250 millions de titre, et cela va permettre à gemini de rentrer dans le capital puisqu'il détiennent 1,66 millions d'actions privilégié, ce qui va se transformer en 166millions d'actions ordinaires, et il vont rajouté pour cela dans le capital 1,6 millions $. Et de plus la société va détenir assez d'actions à un prix autre que symbolique actuellement, et si gemini souhaite prendre le contrôle à l'amiable, cela deviendra possible avec une somme qui devrait contenter les actionnaires, ce qui n'était pas le cas actuellement puisque Gemini a été obligé de le faire sous forme de prêt à un taux cadeau de 2%.

Bonne journée.

PS.: Tu as du travail maintenant pour essayer de trouver la nouvelle stratégie d'oxis (-_°).

http://oxis.investorroom.com/index.php?s=62

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14C

Information Statement Pursuant to Section 14 of
the Securities Exchange Act of 1934

Filed by the Registrant x
Filed by a Party other than the Registrant o

Check the appropriate box:

x Preliminary Information Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
o Definitive Information Statement
o Definitive Additional Materials

OXIS INTERNATIONAL, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Information Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.
o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)
Title of each class of securities to which transaction applies:

(2)
Aggregate number of securities to which transaction applies:

(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)
Proposed maximum aggregate value of transaction:

(5)
Total fee paid:
o Fee paid previously with preliminary materials.

o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)
Amount Previously Paid:

(2)
Form, Schedule or Registration Statement No.:

(3)
Filing Party:

(4)
Date Filed:

OXIS INTERNATIONAL, INC.
468 N. Camden Drive, 2nd Floor
Beverly Hills, California 90210

INFORMATION STATEMENT
January 20, 2011

WE ARE NOT ASKING YOU FOR A PROXY AND
YOU ARE REQUESTED NOT TO SEND US A PROXY.

General Information

This Information Statement is being made available to the stockholders of record of Oxis International, Inc. (“we”, “us”, or “our”, or the “Company”), as of the close of business on January 19, 2011. This Information Statement is being sent to you for information purposes only. No action is requested or required on your part.

This Information Statement is being furnished to you to inform you that the holder of shares representing a majority of the voting power of our securities has adopted, by written consent, resolutions authorizing us to approve and adopt an amendment (the “Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 600,000,000 shares. The Amendment will be filed with the Delaware Secretary of State 20 or more calendar days after the date the Information Statement is first mailed to our stockholders (or, on or after February 9, 2011).

We will pay all costs associated with the preparation and distribution of this Information Statement, including all mailing and printing expenses.

No action is required by you. Because the written consent of a majority of the voting power of our securities to approve the Amendment satisfies all applicable stockholder voting requirements, we are not asking you for a proxy. We are making this Information Statement available to you solely to inform you of the approval of the Amendment by the holder of a majority of the voting power of our shares. Certain rules and regulations of the Securities and Exchange Commission (“SEC”) and Section 228 of the Delaware General Corporation Law (“DGCL”), require that we notify you of these approvals because they were obtained by written consent of the holder of the majority voting power in lieu of a meeting.

This Information Statement is being first sent or given to security holders on or about January 20, 2011.

MEETING NOT REQUIRED

Under Section 242 of the DGCL, an amendment to our certificate of incorporation must be adopted by the Board of Directors and be approved by stockholders holding shares entitling them to exercise at least a majority of the voting power of the company. Section 228 of the DGCL provides that, unless otherwise provided in a corporation’s certificate of incorporation or bylaws, actions required or permitted to be taken at a meeting of the stockholders may be taken without a meeting if a written consent thereto is signed by stockholders holding not less than at least a majority of the voting power of the company. In order to eliminate the costs and management time involved in holding a special meeting, our Board of Directors decided to obtain, and did in fact obtain, the written consent of Theorem Group, LLC, the stockholder that holds the requisite number of votes necessary to authorize or take such action. Our Bylaws also permits action to be taken by written consent of the stockholder or stockholders holding no less than at least a majority of the voting power of the company.

DISSENTERS’ RIGHT OF APPRAISAL

Under Delaware law and our Certificate of Incorporation and Bylaws, no stockholder has any right to dissent to the Amendment, and no stockholder is entitled to appraisal of or payment for their shares of our stock.

OUTSTANDING SHARES AND VOTING RIGHTS

As of January 19, 2011, our authorized capitalization consisted of 150,000,000 shares of common stock (the “Common Stock”), of which 149,513,815 shares were issued and outstanding.

Each share of Common Stock entitles its holder to one vote on each matter submitted to the stockholders.

CONSENTING STOCKHOLDER

The approval of the Amendment requires the consent of no less than at least a majority of the voting power of the Company. Theorem Group, LLC owns, in addition to other securities of the Company, 25,000 shares of Series H Convertible Preferred Stock. The Certificate of Designation of Preferences, Rights and Limitations of the Series H Convertible Preferred Stock provides that each outstanding share of Series H Convertible Preferred Stock entitles the holder thereof to a number of votes equal to (A) the number of shares of Common Stock that such share of preferred stock could, at such time, be converted into (B) multiplied by 100. The Series H Convertible Preferred Stock is currently convertible into 2,500,000 shares of Common Stock. Accordingly, Theorem Group, LLC has the voting power of 250,000,000 shares, which represents more than a majority of voting power of all of our outstanding voting shares. Theorem Group, LLC approved the Amendment on January 5, 2011 by an action taken by written consent.

No consideration was paid for the consent of the consenting stockholder.

INCREASE IN NUMBER OF AUTHORIZED SHARES OF COMMON STOCK

Under our Second Amended and Restated Certificate of Incorporation as currently in effect, we are authorized to issue a total of 150,000,000 shares of Common Stock. As of January 5, 2011, 149,513,815 shares of Common Stock were issued and outstanding. Accordingly, as of that date, there were only 486,185 shares available for future issuance. However, as of January 5, 2011, we had outstanding options, warrants and convertible debentures that, if exercised or converted would result in the issuance of approximately 419,046,703 additional shares of our Common Stock. Since we do not have sufficient authorized shares to accommodate all of our currently outstanding options, warrants and convertible debentures, it is necessary to increase the authorized number of shares of Common Stock.

Our Board of Directors approved an amendment to our Second Amended and Restated Certificate of Incorporation to increase the shares of Common Stock that are authorized for issuance by 450,000,000 shares, bringing the total number of common shares authorized for issuance to 600,000,000. The Amendment amends and restates the first paragraph of Article FOURTH of our Second Amended and Restated Certificate of Incorporation to read as follows:

2

“I. COMMON STOCK

The Company is authorized to issue a total of Six Hundred Million (600,000,000) shares of Common Stock, $0.001 par value per share. Dividends may be paid on the Common Stock as and when declared by the Board of Directors, out of any funds of the Company legally available for the payment of such dividends, and each share of Common Stock will be entitled to one vote on all matters on which such stock is entitled to vote.”

The purpose of the proposed increase in the number of authorized shares of Common Stock is to make additional shares available for issuance by the Company as the Board of Directors deems appropriate or necessary. Based upon our currently available funds, we will have to obtain additional financing in order to fund our ongoing business and operations and meet our working capital needs. We currently anticipate that we will seek to raise additional capital through the sale of additional shares of Common Stock or securities convertible into Common Stock. Unless our Certificate of Incorporation is amended to increase the number of shares of Common Stock we are authorized to sell, we may not have sufficient authorized shares of Common Stock available for these purposes. Additionally, the Company needs to increase the number of authorized shares of Common Stock so that we may issue shares of Common Stock to the existing holders of our derivative securities, including our convertible preferred stock, convertible debentures, warrants and options. Furthermore, additional authorized shares may be needed in the future in connection with possible acquisitions of other companies, businesses or assets, or in connection with establishing strategic partnerships or other business relationships, or for other corporate purposes.

The Board of Directors does not intend to solicit further stockholder approval prior to the issuance of any authorized shares of Common Stock, except as may be required by applicable law. Holders of our Common Stock as such have no statutory preemptive or subscription rights with respect to future issuances of Common Stock.

The holders of Common Stock are entitled to one vote per share on all matters to be voted upon by the stockholders. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the Board of Directors out of funds legally available for that purpose. In the event of our liquidation, dissolution or winding up, the holders of our Common Stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. There are no redemption or sinking fund provisions applicable to our Common Stock.

The increase in the authorized number of shares of Common Stock will not have any immediate effect on the rights of existing stockholders. Any subsequent issuance of such shares could have the effect of delaying or preventing a change-in-control of the Company. Any issuance of additional shares of Common Stock also could have the effect of diluting any future earnings per share and book value per share of the outstanding shares of our Common Stock, and such additional shares could be used to dilute the stock ownership or voting rights of a person seeking to obtain control of the Company. We have no present agreement or commitment, however, to issue any additional shares of Common Stock other than in respect of the exercise or conversion of our outstanding options or warrants.

3

STOCKHOLDINGS OF CERTAIN

BENEFICIAL OWNERS, DIRECTORS AND EXECUTIVE OFFICERS

The following table sets forth, as of January 5, 2011, the number and percentage of shares of Common Stock beneficially owned, directly or indirectly, by each of our directors, the Executive Officers, beneficial owners known by the Company to own more than five percent of the outstanding shares of our Common Stock and by our directors and executive officers as a group. Beneficial ownership is determined in accordance with the Rule 13d-3(a) of the Securities Exchange Act of 1934, as amended, and does not necessarily indicate ownership for any other purpose, and generally includes voting or investment power with respect to the shares and shares which such person has the right to acquire within 60 days of January 5, 2011.

Beneficial Owner(1)
Title of Class of Stock

Amount and Nature of Beneficial Ownership(2)

Percent of Class**

5% Stockholders:

Bristol Investment Fund, Ltd.
Common
31,024,357 (3) 20.8 %
c/o Bristol Capital Advisors, LLC
10990 Wilshire Boulevard, Suite 1410
Los Angeles, CA 90024

Theorem Group, LLC
Common
5,400,000 (4) 3.6 %
10880 Wilshire Blvd., Suite 950
Los Angeles, CA 90024

Current Executive Officers, and Directors:

Anthony Cataldo
Common
6,704,801 (5) 4.5 %
Michael Handelman
Common
250,000 (5) *
Anshuman Dube
Common
-0- (6) *
Thomas Hoog
Common
250,000 (5) *
All current directors, and executive officers as a group (4 Persons)
Common
7,204,801 4.8 %

*
Indicates less than 1.0%

**
Based on 149,513,815 shares of Common Stock outstanding as of January 5, 2011.

(1)
Unless otherwise indicated, the address for each of the individuals listed in the table is c/o Oxis International, Inc., 468 N. Camden Drive, 2nd Floor, Beverly Hills, California, 90210.

(2)
Unless otherwise indicated, the persons named in the table have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by them, subject to applicable community property laws.

(3)
Represents shares issuable upon the exercise of outstanding warrants.

4

(4)
Represents shares issuable upon: (i) the conversion of 25,000 outstanding shares of Series H Convertible Preferred Stock and a 0% Convertible Debenture that is due October 1, 2011, and (ii) the exercise of Series A Warrant to purchase up to 900,000 shares of Common Stock and Series B Warrant to purchase up to 900,000 shares of Common Stock. The foregoing shares of Series H Convertible Preferred Stock, the 0% Convertible Debenture and the Series A Warrant and Series B Warrant limit the ability of the holder thereof to convert such securities if, following such conversion, the holder and its affiliates would beneficially own more than 4.99% of the Company’s then issued and outstanding shares of Common Stock. The Series H Convertible Preferred Stock entitles the holder thereof to a number of votes, without the foregoing 4.99% limitation, equal to (A) the number of shares of Common Stock that such share of preferred stock could, at such time, be converted into (B) multiplied by 100 (or, a voting power of 250,000,000 shares). The foregoing table includes the 2,500,000 shares the Series H Convertible Preferred Stock is convertible into, but does not include the effect of these 250,000,000 votes.

(5)
Consists of shares which may be acquired upon the exercise of options.

(6)
Does not include any shares owned by Theorem Group, LLC described in the table. Mr. Dube is the Managing Member of Theorem Group, LLC.

INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON

Mr. Dube is the Managing Member of Theorem Group, LLC, the owner of 25,000 shares of Series H Convertible Preferred Stock, a 0% Convertible Debenture, a Series A Warrant to purchase up to 900,000 shares of Common Stock, and a Series B Warrant to purchase up to 900,000 shares of Common Stock. Since there is not a sufficient number of authorized shares that can be issued if the currently issued and outstanding debentures and warrants are converted or exercised, as the case may be, the Amendment will enable holders of the Company’s convertible debentures and warrants, including Theorem Group, LLC, to convert and exercise their securities. Except for Mr. Dube’s interest in the Amendment, no director, executive officer, associate of any director, executive officer, has any substantial interest, direct or indirect, by security holdings or otherwise, in the proposed Amendment.

PROPOSALS BY SECURITY HOLDERS

As of the date of this Information Statement, no proposals have been received by the Company.

ADDITIONAL INFORMATION

We are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith, we file periodic reports, documents and other information with the SEC relating to our business, financial statements and other matters. Such reports and other information may be inspected and are available for copying at the offices of the SEC, 100 F Street, N.E., Washington, D.C. 20549 or may be accessed at www.sec.gov. Information regarding the operation of the public reference rooms may be obtained by calling the SEC at 1-800-SEC-0330.

5

We will provide, upon request and without charge, to each stockholder receiving this Information Statement a copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and a copy of our Quarterly Report on Form 10-Q for the three months ended September 30, 2010, including the financial statements, as filed with the SEC. You are encouraged to review the Annual Report, the Quarterly Report and any subsequent information we filed or will file with the SEC and other publicly available information.

January 20, 2011
By Order of the Board of Directors,

/s/ ANTHONY CATALDO
Anthony Cataldo
Chief Executive Officer and Chairman of the Board

https://www.fuelteam.wallst.com/modules/secfilings/drawFiling.asp?docKey=137-000010965711000003-5AD9O93SO81ITADMNBPPDTGUTJ&formType=PRE%2014C&date=1/7/2011&docFormat=TXT

9 de 31 - 10/1/2011 01:34

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Bsr Xcountry

Merci pour cette info.
Nous verrons comment le marché réagira ...

10 de 31 - 10/1/2011 01:44

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

2010-12-24 10:54:26 - OXIS International, Inc. (OXIS) - Financial and Strategic SWOT Analysis Review - a new company profile report on companiesandmarkets.com

Oxis International, Inc. (OXIS) is principally engaged in the research and development of neutraceutical products for sale to general consumers. The company´s main divisions are Ergothioneine and Therapeutics. It owns Biocheck, a provider of enzyme immunoassay research services and products in the immunoassay segment of the clinical diagnostics market. Its research and development activities are principally into patent development and
other research programs and projects. The company operates in the US, Canada, Mexico, Europe, Middle East, Africa, Asia Pacific and Other Countries. It has three subsidiaries namely, BioCheck, Inc, Oxis Consumer Products (OCP) and OXIS Therapeutics, Inc.

11 de 31 - 10/1/2011 16:48

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Oxis International est spécialisé dans la recherche, le développement et la vente de produits nutraceutiques dans le domaine de la réduction du stress oxydatif. L'activité du groupe s'organise essentiellement autour de 2 familles de produits :
- produits nutraceutiques : comprenant L-Ergothioneine (ERGO), un antioxydant naturel d'acides aminés utilisé comme un composant anti-âge potentiel dans les produits de soins et vendus par l'industrie cosmétique, et comme composant dans les produits agissant pour la fertilité vétérinaire ;
- composants thérapeutiques : anti-inflammatoires, et antioxydants avec des applications potentielles dans le traitement des maladies de dégénérescence (Alzheimer et Parkinson), les maladies cardio-vasculaires et le diabète.

http://www.oxis.com/

Principaux actionnaires:

1. Bristol Investment Fund: 32,86%

2. Dirigeants et Administrateurs: 2,64%

12 de 31 - 21/1/2011 00:04

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Company News
OXIS OXIS
Oxis International, Inc. OTCBB

Back to Headlines | Print Version | ShareThis

OXIS Files Patent Application For Methods And Compositions Using Ergothioneine

(RTTNews) - OXIS International, Inc., (OXIS.OB) Monday said it has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office.

The company stated that the application relates to the use of Ergothioneine compositions containing one or more additional nutraceutical compounds to improve a variety of health related factors.

The application also includes information and data from various clinical and animal studies examining Ergothioneine's safety profile and benefits relating to health issues associated with oxidative stress.

For comments and feedback: contact editorial@rttnews.com

Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=201012200754RTTRADERUSEQUITY_0362#ixzz1BcTFZTo4

13 de 31 - 08/2/2011 23:15

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

In mid-November 2010 OXIS will launch its first product, ErgoFlexÂ®, a potent formula for joint pain relief. This launch will be supported by the start of a pilot study on joint pain, inflammation and range of motion. In addition, we have active development programs underway with several products. Later this year and into early 2011, OXIS will launch additional products including formulas directed at boosting energy/anti-aging, cardiovascular health and improved vision.

We will employ direct mail to build awareness and acceptance of these products, followed by Internet sales and TV and radio infomercials, all of which are proven to be very effective with nutrition and personal care products. Compared with traditional retail outlets, these direct-to-consumer channels offer significantly higher margins and a potentially more rapid market entry.

Over time we plan to go beyond supplements to introduce ERGO-based functional foods and beverages such as nutrition bars and energy drinks, and a line of personal care products such as anti-aging creams, advanced cosmetics and hair and scalp treatments.

Although we are very pleased with the progress in recent months, there are several important milestones we plan to achieve over the coming months. These include publishing additional safety and toxicology data on ERGO with the objective of gaining an FDA designation of generally recognized as safe (GRAS), raising new funds and completing a capital restructuring, building a strong multilevel marketing network to complement our other direct-to-consumer channels, introducing additional nutraceutical and cosmeceutical products, expanding our Board of Directors and holding the First World Congress on Ergothioneine in Los Angeles in July 2011.

On behalf of OXIS International's management and Board, we thank you for your support and look forward to reporting on our future accomplishments and success.

Sincerely,

14 de 31 - 08/2/2011 23:17

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

http://www.chloregy.com/home/health/187294-oxis-international-announces-letter-to-stockholders-posted-on-website-ppc

15 de 31 - 08/2/2011 23:25

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Leadership

News Releases

SEC Filings
Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week
Jan 31, 2011

BEVERLY HILLS, Calif., Jan. 31, 2011 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX™ joint health formula, launched commercially in December 2010. Specifically, the study found that reduction of pain was statistically significant after as little as one week of ERGOFLEX use. Similar improvements were seen with range of motion. Benefits continued during the six weeks subjects took ERGOFLEX, and for some the benefits persisted during the subsequent six-week washout period.

ERGOFLEX is the only joint health complex containing the powerful antioxidant L-Ergothioneine (ERGO) and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health. It is the first in a series of products built around the ERGO platform that are planned by OXIS.

"These powerful and statistically significant final results strongly suggest that ERGOFLEX can provide significant quick and lasting relief from mild-to-moderate joint pain while improving range of motion, which results in an improved quality of life," said Bernie Landes, President of OXIS International. "These clinically demonstrated results represent an important breakthrough for those tens of millions of Americans who suffer with chronic joint pain and diminished range of motion. While most joint pain products only address the symptoms, ERGOFLEX targets and relieves oxidative stress, which frequently is the underlying cause of joint ailments. It also provides a suite of extensively researched natural ingredients that help maintain the structural integrity of joints and relieve pain."

The study included 12 subjects taking ERGOFLEX at the recommended dose of two capsules per-day for six weeks, followed by a six-week washout period. At study start the participants exhibited mild-to-moderate chronic pain affecting range of motion in several areas, including neck, shoulders, arms, lower back, hips and knees. The participants also had not consumed other joint relief supplements or juices with high antioxidant content for a period of two months prior to study intake.

Subjects were examined in the lab at study start (day 0) and at weeks one, six and 12; in addition, questionnaires were conducted weekly via phone to monitor health changes. Each subject was evaluated using 27 distinct range-of-motion measurements conducted on the major areas of discomfort and on the body's entire vertical axis. The assessments were performed by Dr. David Ager, DC at Cascade Spine and Rehabilitation clinic, using the J-Tech dual digital inclinometry. All 12 subjects completed the 12-week study.

Based on the results from this initial trial, OXIS plans to design and implement a placebo-controlled, randomized clinical trial with ERGOFLEX.

OXIS has previously announced the First World Congress on Ergothioneine to be held at UCLA in July 2011. This study reflects OXIS's continuing commitment to building its business on a foundation of sound science.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets. For more information, please visit www.oxis.com.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may," "potential" or the negative of those words or other similar expressions words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks and uncertainties inherent in our business, including, without limitation the risks of obtaining possibly required regulatory approvals, the timing of product introductions, the level of market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

SOURCE OXIS International, Inc.

For further information: Lippert/Heilshorn & Associates: Don Markley, +1-310-691-7100, dmarkley@lhai.com

16 de 31 - 09/2/2011 23:24

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

http://finance.yahoo.com/news/OXIS-International-Launches-prnews-1730074065.html?x=0&.v=1

Rappel de l'article communiqué en décembre 2010

17 de 31 - 09/2/2011 23:40

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Bsr a tous...
Xcontry, voici l'article qui devrait répondre sur les modalités entre Oxis et GEMINI

OXIS International Signs $1M Investment with Gemini Pharmaceuticals
Source: OXIS International, Inc.
November 11, 2010 12:01 AM
Article ToolsShareEmailPrintReprintsCommentsOXIS International, Inc., (OTC Bulletin Board: OXIS; Paris: OXI) announced that Gemini Pharmaceuticals has made a $250,000 strategic equity investment in the Company accompanied by a $750,000 line of credit.

Under terms of the agreement, Gemini is purchasing 1,666,667 convertible preferred shares at $0.15 per share, approximately a 50% premium over the current market price of OXIS' common shares. The credit line is available to OXIS at a rate of prime plus 2% per year.

"We believe this strategic investment from Gemini represents an important endorsement of our Ergothioneine technology and the potential of our planned line of supplements and nutrition products," said Anthony Cataldo, Chief Executive Officer. "Purchasing shares at an above-market price and providing credit at 'A-class' terms reflects Gemini's confidence in our management team and operating plan. As our primary product development and manufacturing partner, Gemini understands the unique and valuable health benefits of ERGO, as well as the strong proprietary position OXIS holds as the sole source provider for the health and wellness and personal care markets."

Gemini was earlier selected by OXIS to assist in the development of and to produce a series of nutritional supplements built on a proprietary platform incorporating the Company's versatile anti-oxidant, L-Ergothioneine (ERGO). A patented process developed and owned by OXIS is utilized to synthesize commercial quantities of ERGO in a highly soluble and highly stable form suitable for use in a wide variety of dietary supplements, functional foods and beverages, topical anti-aging and cosmetic lotions, creams and other personal care products, as well as therapeutics.

About Gemini Pharmaceuticals

Gemini is a leading provider of research, development, manufacturing logistic and design services to the pharmaceutical and nutritional industries. This support, combined with its cGMP certification for both OTC drugs and vitamin/nutritional supplements, guarantees that its customers only will receive the highest quality products.

Gemini Pharmaceuticals has been a private label manufacturer of OTC's, dietary supplements, herbs and nutritional products for almost 30 years. Gemini is fully licensed and registered with the Food and Drug Administration (FDA), the Drug Enforcement Agency (DEA) and the New York State Board of Pharmacy. In addition, Gemini's cGMP certification and state-of the- art, on-site laboratory ensure that all products manufactured in its facility exceed the strictest quality control procedures throughout all stages of production and packaging.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets.

18 de 31 - 09/2/2011 23:47

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

http://www.bloomberg.com/apps/news?pid=conewsstory&tkr=OXIS:US&sid=aFhCL0KInTdA

19 de 31 - 23/2/2011 01:37

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

En accompagnant le développement ses produits , Oxis Intl trouve ainsi des investissements et des appuis séreux de partenaires qui sont aussi issu du milieu de la recherche jusqu'a la conception des molécules. Ainsi
Cette stratégie est profitable sur le plan des avancés de la recherche et bénifique sur l'étendu du réseau commerciale quand le produit est en phse de commercialisiation.

Les besoins en molécules sont indéniables dans le secteur de la santé :pharmaceutique, para-pharmacie, cosmétique, diéthetique, et du bien être, au point de créer des fusions entre firme ....

OXIS INTL : OXIS International to Present at the Lippert/Heilshorn Life Sciences and Medtech Virtual Conference on February 17
02/14/2011 | 08:05 am

BEVERLY HILLS, Calif., Feb. 14, 2011 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Paris: OXI) today announced that Anthony Cataldo, Chief Executive Officer, and Bernie Landes, President, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-Line Forum on Thursday, February 17, 2011 at 12:30 p.m. Eastern (9:30 a.m. Pacific).

A webcast of the presentation will be accessible online on at the PrecisionIR event site: http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=163285. An archived version will be available for 30 days.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets.

SOURCE OXIS International, Inc.

20 de 31 - 28/2/2011 16:11

djurjura Messages postés: 835 - Membre depuis: 21/2/2008

Oxis Intl : L'Ergoflex soulage les douleurs articulaires en une semaine !
Lundi 31 janvier 2011 à 08:58 Imprimer
Formation CFD: Cliquez ici

(Tradingsat.com) - OXIS International fait état lundi matin de résultats définitifs très favorables d'une étude clinique destinée à évaluer les effets bénéfiques de son produit Ergoflex, lancé commercialement en décembre 2010.

« Plus précisément, l'étude a révélé que la réduction de la douleur a été statistiquement significative après seulement une semaine d'utilisation d'Ergoflex », souligne le laboratoire cotée à Paris et à New York. De plus, « des améliorations similaires ont été observées sur l'amplitude des mouvements », grâce à ce complément diététique destiné à soulager les douleurs articulaires.

Enfin, « les bénéfices ont été constants pendant les six semaines de traitement des sujets, et pour certains, il se sont prolongés pendant les six semaines suivantes », ajoute OXIS.

F. B. - Copyright (c) 2006-2011 Tradingsat.com. Tous droits réservés.

Suivant > >

Afficher tous les Messages

Retourner à la liste

Rafraîchir

31 Réponses
1 2

Messages à suivre: (31)
Dernier Message: 03/Oct/2012 15h26

Connexion Requise

Vous devez vous identifier pour répondre à ce message